Colorado Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Colorado Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,278	Closed	-$16K	–	80
2023 Q3	$16K	Hold	2,278	–	–	0.01%	80
2023 Q2	$12K	Hold	2,278	–	–	0.01%	76
2023 Q1	$7K	Sell	2,278 -2,277	-50%	-$8.65K	0.01%	77
2022 Q4	$18K	Buy	4,555 +2,727	+149%	+$11.1K	0.02%	75
2022 Q3	$7K	Hold	1,828	–	–	0.01%	72
2022 Q2	$24K	Hold	1,828	–	–	0.02%	79
2022 Q1	$9K	Hold	1,828	–	–	0.01%	78
2021 Q4	$12K	Hold	1,828	–	–	0.01%	79
2021 Q3	$56K	Hold	1,828	–	–	0.04%	72
2021 Q2	$59K	Hold	1,828	–	–	0.04%	74
2021 Q1	$69K	Hold	1,828	–	–	0.05%	73
2020 Q4	$87K	Hold	1,828	–	–	0.06%	73
2020 Q3	$59K	Hold	1,828	–	–	0.05%	69
2020 Q2	$80K	Hold	1,828	–	–	0.07%	73
2020 Q1	$59K	Buy	+1,828	New	+$84K	0.05%	74
2017 Q1	–	Sell	-697	Closed	-$50K	–	71
2016 Q4	$50K	Hold	697	–	–	0.05%	66
2016 Q3	$95K	Hold	697	–	–	0.09%	63
2016 Q2	$120K	Hold	697	–	–	0.12%	61
2016 Q1	$131K	Hold	697	–	–	0.13%	64
2015 Q4	$245K	Buy	+697	New	+$274K	0.27%	55

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Colorado Capital Management's GYRE Position: Q4 2023 in Review

Colorado Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 2,278 shares — an estimated $16K sold.

Colorado Capital Management first reported a position in GYRE in Q4 2015 and held it in 20 quarters. The position peaked at $245K in Q4 2015. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

Colorado Capital Management reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
Colorado Capital Management sold 2,278 Gyre Therapeutics shares in Q4 2023, an estimated $16K.
Colorado Capital Management first reported a position in Gyre Therapeutics in Q4 2015 and held it in 20 quarters.
Colorado Capital Management's Gyre Therapeutics position peaked at $245K in Q4 2015.
16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Colorado Capital Management's 13F filing for Q4 2023, filed 19 Jan 2024.